trations of epinephrine and norepinephrine and to measure myocardial norepinephrine balance (arterialcoronary sinus concentration times coronary sinus flow).13 Myocardial norepinephrine balance is the convergence of norepinephrine uptake and release in the heart and has been shown to more closely reflect myocardial sympathetic tone than levels of circulating catecholamines. 11 In this study, arterial and coronary sinus epinephrine and norepinephrine concentrations were measured before and after giving captopril to 14 patients with moderate-to-severe exercise-induced angina. Also, the effects of captopril on exercise-induced angina were assessed in a further 21 patients.
MOST VASODILATORS decrease arterial pressure and thus myocardial work, but their antianginal efficacy is limited by reflex tachycardia.' 2 Use of captopril has the advantage that it does not cause reflex tachycardia and in previous work we have shown that the drug decreased myocardial oxygen consumption when given to patients with congestive heart failure and coronary artery disease. 3 We have recently shown that captopril decreases myocardial oxygen consumption when given to hypertensive patients with coronary artery disease.4 These effects may be the result of decreased myocardial sympathetic tone.5'-2 If this is true, captopril might prove useful in the treatment of patients with coronary artery disease.
To measure myocardial sympathetic activation in vivo in man, it is important to measure arterial concen-trations of epinephrine and norepinephrine and to measure myocardial norepinephrine balance (arterialcoronary sinus concentration times coronary sinus flow).13 Myocardial norepinephrine balance is the convergence of norepinephrine uptake and release in the heart and has been shown to more closely reflect myocardial sympathetic tone than levels of circulating catecholamines. 11 In this study, arterial and coronary sinus epinephrine and norepinephrine concentrations were measured before and after giving captopril to 14 patients with moderate-to-severe exercise-induced angina. Also, the effects of captopril on exercise-induced angina were assessed in a further 21 patients.
Materials and methods
Part I -hemodynamic protocol. Fourteen patients (six women and eight men) with stable angina who responded poorly to treatment with calcium-entry blockers and with fl-blockers and nitrates were selected for the study. Exclusion criteria included creatinine level of greater than 2 mg/dl, proteinuria of greater than 1 g/day, or presence of any immunologic disease. To avoid induction of hypotension, only patients with systolic nificant obstructive lesions (>50% stenosis) of the left anterior descending, left circumflex, and right coronary arteries; three had obstructive lesions of the left anterior descending and right coronary arteries and a single obstruction of the left anterior descending artery was present in three patients. All four patients who refused to undergo coronary arteriography had documented myocardial infarctions and stable angina. Six of the 14 patients had received [l-blockers, nine had taken calcium-entry blockers, and 11 had been on nitrates. Diuretics, ,3-blockers, and calcium-entry blockers were discontinued at least 24 hr before the study, and nitrates were discontinued 12 hr before the study. Each patient gave informed written consent.
In each patient the right side of the heart was catheterized with a flow-directed, balloon-tipped No. 7 Swan-Ganz thermodilution catheter inserted percutaneously through the right subclavian vein to record right atrial pressure (RAP) and pulmonary capillary wedge pressure (PCWP Medication and stress testing. Each patient gave informed, written consent. All vasodilators had been discontinued for at least 48 hr, and each patient received one-half of a tablet from bottle A, which contained either placebo or 12.5 mg doses of captopril. The patients then received one half tablet daily for 1 week. On day 7, if systolic arterial pressure remained greater than 100 mm Hg and if there had been no clinical deterioration, a full tablet from bottle A was given daily for 7 days. Seventeen of the 21 patients received full tablets of captopril and 20 of 21 patients received the full placebo tablets. On day 14, 45 min APatients that had decreased systolic arterial pressure while on captopril of at least 1 0 mm Hg at rest and during exercise when compared with placebo.
after receiving medication A, each patient underwent a symptom-limited, modified Bruce exercise stress test during which heart rate and blood pressure were measured every minute until anginal threshold. The same protocol was followed during administration of medication B, and once the last patient completed the study, the code was broken. All stress tests were completed between 10 and 11 A.M., at least 3 hr after a light breakfast.
Statistical analysis. The data obtained before and after captopril were compared by a two-tailed paired t test. The data from the responders and nonresponders to captopril were compared by a two-tailed unpaired t test. The correlation between serum renin and the decrease in arterial pressure was assessed by linear regression. All reported values are mean + SD unless otherwise specified.
Results
Hemodynamic protocol Patient response. The patients received between 12.5 and 594 mg of captopril (mean 328 ± 235 mg). The responders (>10 mm Hg decrease in mean arterial pressure) received 127 + 86 mg of captopril and the nonresponders 518 + 142 mg. As expected, the decrease in arterial pressure was directly proportional to baseline renin value (figure 1). During the short-term study, no patient developed signs or symptoms of hypotension or cardiac ischemia. All 14 patients are still alive and their conditions are improved at a mean follow-up of 5.5 months (range 4 to 8 months) and only one patient has been readmitted for cardiac ischemia (noctural angina). At last follow-up, the mean NYHA class of the patients had improved from 3.0 ± 0.8 to 1.6 ± 0.8 (figure 2). Captopril therapy has been discontinued in only two patients, in one because of hypotensive symptoms and in one because of 5 g proteinuria that had been underestimated before captopril was administered. The long-term daily dose of captopril was 50 to 125 mg/day. Systemic hemodynamics (table 1) . The control mean arterial pressure in the patients we chose for study was slightly elevated because we wanted to avoid induction of hypotensive symptoms (inclusion criteria systolic arterial pressure >120 mm Hg). Captopril decreased mean arterial pressure without causing reflex tachycardia. As a result, the decrease in rate-pressure product was proportional to the decrease in arterial pressure. After captopril stroke work index and the cardiac index were both slightly decreased, but pulmonary capillary wedge pressure was in the high normal range (14 + 9 mm Hg). Captopril decreased systemic vascular resistance and stroke work index, but did not change cardiac index or pulmonary capillary wedge pressure.
Coronary hemodynamics ( Control Captopri I FIGURE 3. Changes in myocardial lactate extraction caused by shortterm captopril therapy. In most patients myocardial lactate extraction tended to increase, but in one patient it decreased to 1% and one patient produced lactate. Captopril had no short-term hemodynamic effect in these two patients, but the long-term clinical improvement observed in these two patients may be explained by the documented very short and long-term decrease in arterial pressure observed after the addition of captopril. We found a linear relationship between circulating renin levels and the decrease in arterial pressure caused by captopril. In the short-term hemodynamic study, the average dose of captopril given was higher than that normally given for two reasons. First, the nonresponders received large doses of captopril to ensure that they were truly nonresponders, and second, although the dose given to the responders was much smaller (127 + 86 mg), it would have been even smaller if our end point of a 10 mm Hg decrease in mean arterial pressure had not been strictly enforced. Most responders had a decrease in mean arterial pressure of at least 5 mm Hg after 25 mg of captopril, but we continued to double the dose until a 10 mm Hg decrease in mean arterial pressure was achieved.
After the short-term study, when captopril was added to the antianginal drug regimen of patients with low or normal renin values, it caused a significant (>10 mm Hg) decrease in arterial pressure. By witholding diuretics and vasodilators before the study, we may have artificially decreased circulating renin below prestudy levels and when these drugs were reintro-FIGURE 4. Lack of reflex increase in sympathetic tone despite a significant decrease in arterial pressure. The responders (> 10 mm Hg decrease in mean arterial pressure after the addition of captopril) had higher control renin activities. Despite a significant decrease in arterial pressure, the responders tended to show a decrease in myocardial norepinephrine (NE) balance. Captopril had no effect on the myocardial norepinephrine balance of the nonresponders. A = change. *p < .05 for responders vs nonresponders.
duced, captopril may have inhibited restimulation of the renin-angiotensin system. This would also explain why patients with low renin levels and minor changes in arterial pressure during the short-term study also improved with the addition of captopril during the long-term study. In the stress test study, the frequencies of use of /3-blockers (14 of 21 patients) and diuretics (six of 21 patients) may help explain why only 10 of 21 patients had significant decreases in systolic arterial pressure.22 23 In the hemodynamic study our patients improved significantly when captopril was added to their drug regimens. Although antianginal efficacy was only assessed by a subjective NYHA classification, the apparent improvement was remarkable and probably represents a true beneficial effect. Although we could not measure regional coronary blood flow or metabolism after captopril, myocardial oxygen consumption decreased overall and myocardial metabolism did not deteriorate. In the stress test study, only those patients in whom rate-pressure product decreased had improved exercise tolerance, suggesting that a decrease in myocardial oxygen consumption is the major antianginal mechanism of captopril. Indeed, of all the antian- ginal drugs used, only nitrates have consistently been shown to increase rate-pressure product at anginal threshold.2F26
As opposed to most other vasodilators captopril decreases arterial pressure without causing reflex tachycardia. 1 2, 27 This was true for the patients who were not receiving fl-blockers in both the short-term hemodynamic and stress test studies. These findings correlate well with the lack of reflex myocardial sympathetic activation that we found in our study, and suggest that the concomitant use of fl-blockers is not necessary for antianginal efficacy of captopril. However, because in the long-term phase of the hemodynamic study captopril was added to some other antianginal drug therapy in 12 of 14 patients and because 14 of the 21 patients in the stress test study were also on fl-blockers, we can only conclude that captopril is a useful adjunct in the treatment of angina.
How captopril prevents reflex myocardial sympathetic activation is not clear, but angiotensin-converting enzyme inhibition is the probable mechanism. Angiotensin increases sympathetic activity by central and peripheral means. In conclusion, captopril decreases mean arterial pressure without causing a reflex increase in myocardial sympathetic tone. By virtue of the fact that it decreases myocardial oxygen consumption, captopril may prove a useful adjunct to the antianginal drug regimens of patients with systolic arterial pressures greater than 120 mm Hg.
